Etirinotecan pegol Completed Phase 3 Trials for Locally Recurrent Breast Cancer / Metastatic Breast Cancer (MBC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01492101The BEACON Study (Breast Cancer Outcomes With NKTR-102)